Effective April 1, 2022: Dupixent Benefits Medicaid and CHIP

March 15, 2022

What is New?
Effective April 1, 2022, Blue Cross and Blue Shield of Texas (BCBSTX) was advised that the Vendor Drug Program (VDP) will remove Dupixent for procedure codes J3490 and J3590 from the National Drug Code (NDC) to the Healthcare Common Procedure Coding System (HCPCS) Crosswalk. Dupixent is currently covered under Pharmacy benefit; therefore, it should not affect patient’s ongoing therapy.

You are being notified by BCBSTX because you have encounters submitted for Dupixent under the medical benefits.


For questions or additional information, please:


The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. References to other third-party sources or organizations are not a representation, warranty or endorsement of such organization. Any questions regarding those organizations should be addressed to them directly. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.